AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22771160
Drug: 0.12% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% chlorhexidine (oral care with a toothbrush and antiseptic gel twice a day)
Trial: 22771160
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral care with a toothbrush and non-antiseptic gel twice a day)
Trial: 17599102
Drug: Zinacef (Cefuroxime)
RxNorm normalized name: cefuroxime Injection [Zinacef]
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinacef (Cefuroxime) 1.5 g intravenously at induction and 750 mg six hourly for 12 hours (Group 2)
Trial: 17599102
Drug: Ciprotab (ciprofloxacine)
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprotab (ciprofloxacine) 400mg intravenously at induction and 200mg six hourly for 12 hours (Group 3)
Trial: 17599102
Drug: Cost-effectiveness comparison
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost-effectiveness comparison of the three antibiotics
Trial: 10220207
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro injected at 0 min before a standard lunch with a mid-afternoon snack
Trial: 7882475
Drug: Angiopeptin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiopeptin (3 mg per 24 hours before PTCA followed by 6 mg per 24 hours after PTCA)
Trial: 2122016
Drug: Intravenous L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous L-carnitine (50 mumol/kg/day for 7 days, then 100 mumol/kg/day for 7 days)
Trial: 26265063
Drug: Amoxicillin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (1 g) 1 h before surgery + 500 mg 8/8 h for 7 days
Trial: 26265063
Drug: Amoxicillin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (1 g) 1 h before surgery + placebo (identical appearance to G1) 8/8 h for 7 days
Trial: 26265063
Drug: Placebo 1
RxNorm normalized name: placebo 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 h before surgery and 500 mg 8/8 h for 7 days
Trial: 17302696
Drug: Intracoronary enalaprilat
RxNorm normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary enalaprilat (EN), 50 mug, administered immediately after reperfusion
Trial: 17302696
Drug: Placebo (PL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PL) administered immediately after reperfusion
Trial: 9330414
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 50 micrograms twice daily (b.i.d.)
Trial: 9330414
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate (SCG) 20 mg four times daily (q.i.d.)
Trial: 7953445
Drug: Anterograde delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterograde delivered cardioplegic solution (Group A, n = 19)
Trial: 7953445
Drug: Retrograde delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrograde delivered cardioplegic solution (Group B, n = 17)
Trial: 6385797
Drug: Continued chemotherapy
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued chemotherapy (n=46)
Trial: 31246894
Drug: Indapamide 1.5
RxNorm normalized name: indapamide 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide 1.5 mg sustained release/Amlodipine 5 mg SPC
Trial: 31246894
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg/Valsartan 80 mg SPC
Trial: 16409523
Drug: Using the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using the drug on prescription (PD)
Trial: 15245937
Drug: Sacral nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacral nerve stimulation therapy
Trial: 15245937
Drug: Delayed implant
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed implant group (Control)
Trial: 6472116
Drug: Diet A
RxNorm normalized name: Diet Aid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet A (360 kcal, 1.5 g egg protein per kg IBW, no carbohydrate)
Trial: 6472116
Drug: Diet B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet B (340 kcal, 0.8 g egg protein per kg IBW, 0.7 g carbohydrate per kg IBW)
Trial: 31912474
Drug: diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: diclofenac sodium 50 mg bid
Trial: 31912474
Drug: tamsulosin 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tamsulosin 0.2 mg sid
Trial: 31912474
Drug: combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of tamsulosin and diclofenac sodium
Trial: 30277539
Drug: Genetically predicted
RxNorm normalized name: Burosumab (genetical recombination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetically predicted fasting insulin
Trial: 28433432
Drug: Low-Dose-Rate Prostate
RxNorm normalized name: Sus scrofa prostate preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Dose-Rate Prostate Brachytherapy (LDR-PB) boost
Trial: 28433432
Drug: Dose-Escalated External
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-Escalated External Beam Radiation Therapy (DE-EBRT) boost
Trial: 23611930
Drug: Nitrofurantoin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrofurantoin (100 mg 2 times a day for 3 days)
Trial: 20724299
Drug: Standard surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard surgical treatment; n = 90
Trial: 19785725
Drug: Intracoronary abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary abciximab administration
Trial: 19785725
Drug: Intravenous abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous abciximab administration
Trial: 16400064
Drug: Mixed carotenoids
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed carotenoids (beta‐carotene, lutein, and lycopene; 4 mg each)
Trial: 16400064
Drug: Beta‐carotene (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta‐carotene (12 mg)
Trial: 14965157
Drug: Adverse drug
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse drug event tracking calendar provided to the intervention group
Trial: 9018184
Drug: Oral methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral methylprednisolone (2 mg/kg)
Trial: 9018184
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone (2 mg/kg)
Trial: 9018184
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (oral and i.v.)
Trial: 8475622
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of aspirin for asymptomatic patients
Trial: 3530595
Drug: U-40 insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: U-40 insulin
Trial: 3530595
Drug: U-100 insulin
RxNorm normalized name: SafeSnap 1mL U-100 Insulin Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: U-100 insulin
Trial: 29773079
Drug: Linagliptin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin (5 mg once daily for 12 weeks)
Trial: 20202800
Drug: Drug Attitude
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug Attitude Inventory (DAI) assessment
Trial: 18375253
Drug: Rosiglitazone added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone added to metformin (RM)
Trial: 16470423
Drug: Ibuprofen (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (1 week postoperatively)
Trial: 16470423
Drug: Ibuprofen (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (2 weeks postoperatively)
Trial: 16470423
Drug: Ibuprofen (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (combined treatment)
Trial: 12351281
Drug: gabapentin 1200
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: gabapentin 1200 mg/d
Trial: 30475165
Drug: Transdermal glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal glyceryl trinitrate (given for four days)
Trial: 10983860
Drug: Pivampicillin 700
RxNorm normalized name: pivampicillin
DrugBank: Pivampicillin (DB01604)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivampicillin 700 mg twice daily for 10 days
Trial: 20498136
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of lorazepam
Trial: 19112786
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of pre-oxygenated HBOC-201
Trial: 19112786
Drug: Dry occlusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry occlusion (without HBOC-201 infusion)
Trial: 16404407
Drug: sibutramine 10
RxNorm normalized name: sibutramine 10 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sibutramine 10 mg once daily plus behavioral therapy
Trial: 16404407
Drug: behavioral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: behavioral therapy alone (control)
Trial: 10805062
Drug: Emedastine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emedastine (4 mg q.d.)
Trial: 10805062
Drug: Emedastine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emedastine (2 mg b.i.d.)
Trial: 10805062
Drug: Cetirizine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (10 mg q.d.)
Trial: 4028596
Drug: Tc‐99m pyrophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tc‐99m pyrophosphate (PYP) with 3.4 mg of stannous chloride
Trial: 4028596
Drug: Tc‐99m methylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tc‐99m methylene diphosphonate (MDP) with 3.4 mg of stannous chloride
Trial: 4028596
Drug: Tc‐99m methylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tc‐99m methylene diphosphonate (MDP) with 1.0 mg of stannous chloride
Trial: 24611852
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care therapy (Controls)
Trial: 14639675
Drug: Pramipexole (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole (1.5 mg t.i.d.)
Trial: 14639675
Drug: Pergolide (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pergolide (1.5 mg t.i.d.)
Trial: 8676625
Drug: Fludarabine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine (25 mg/m2 per day on days 1-5 for six courses)
Trial: 8676625
Drug: CAP (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAP (cyclophosphamide 750 mg/m2 per day and doxorubicin 50 mg/m2 per day on day 1, and prednisone 40 mg/m2 per day on days 1-5 for six courses)
Trial: 6093845
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose of ketoconazole
Trial: 25289840
Drug: Low-load resistance
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-load resistance training with concurrent blood flow restriction (BFR)
Trial: 22016276
Drug: Isotretinoin 1
RxNorm normalized name: isotretinoin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotretinoin 1 mg/kg/day (Group A)
Trial: 22016276
Drug: Isotretinoin 1
RxNorm normalized name: isotretinoin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotretinoin 1 mg/kg alternate day (Group B)
Trial: 22016276
Drug: Isotretinoin 1
RxNorm normalized name: isotretinoin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotretinoin 1 mg/kg/day for one week/four weeks (Group C)
Trial: 22016276
Drug: Isotretinoin 20
RxNorm normalized name: isotretinoin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotretinoin 20 mg every alternate day for 16 weeks (Group D)
Trial: 16883263
Drug: Clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300 mg loading dose, followed by 75 mg/day after Day 2) in addition to conventional therapy (TLT, aspirin, statin, ACE inhibitor, beta-blocker)
Trial: 16883263
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy only (TLT, aspirin, statin, ACE inhibitor, beta-blocker)
Trial: 9928580
Drug: Alternating adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating adjuvant chemotherapy
Trial: 8035946
Drug: Albendazole (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (15 mg/kg/d) for 1 week
Trial: 30488800
Drug: Deprox 500®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deprox 500® (2 tablets/day for 6 weeks)
Trial: 30488800
Drug: Serenoa repens
RxNorm normalized name: Serenoa Repens Fruit
DrugBank: Saw palmetto (DB14360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serenoa repens (320 mg, 1 tablet/day for 6 weeks)
Trial: 21921100
Drug: Strategy 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strategy 2 (referral if 2 out of 5 criteria are positive: inflammatory back pain, HLA‐B27, sacroiliitis detected by imaging, positive family history of ankylosing spondylitis, or good treatment response to NSAIDs)
Trial: 19734968
Drug: Surgery (preferred
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery (preferred treatment)
Trial: 19734968
Drug: Various treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatment modalities (not specified)
Trial: 15315512
Drug: Pregabalin (effective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (effective dose range 150-600 mg/day)
Trial: 15315512
Drug: Pregabalin (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (two times daily vs three times daily)
Trial: 11143188
Drug: 7-day intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day intravenous eflornithine (100 mg/kg every 6 h)
Trial: 9269608
Drug: Influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza vaccine and bacterial immunostimulant
Trial: 3690187
Drug: BCG Pasteur
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG Pasteur (L'Institut Pasteur, France)
Trial: 22094636
Drug: TetraMen-T (alternative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TetraMen-T (alternative formulations)
Trial: 22094636
Drug: Neisvac-C (licensed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neisvac-C (licensed adjuvanted serogroup C conjugate vaccine)
Trial: 20797475
Drug: Flaxseed lignan
RxNorm normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed lignan (SDG) 100 mg/d
Trial: 20797475
Drug: Flaxseed lignan
RxNorm normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed lignan (SDG) 20 mg/d
Trial: 12755526
Drug: Propofol target
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol target controlled infusion at 4 mcg/mL
Trial: 12755526
Drug: Propofol target
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol target controlled infusion at 5 mcg/mL
Trial: 12755526
Drug: Propofol target
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol target controlled infusion at 6 mcg/mL
Trial: 11184063
Drug: Dietary therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary therapy candidates according to NCEP II guidelines
Trial: 11184063
Drug: Dietary therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary therapy candidates according to European guidelines
Trial: 11184063
Drug: Antilipemic drug
RxNorm normalized name: ANTILIPEMIC AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antilipemic drug therapy candidates according to NCEP II guidelines
Trial: 11184063
Drug: Antilipemic drug
RxNorm normalized name: ANTILIPEMIC AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antilipemic drug therapy candidates according to European guidelines
Trial: 11184063
Drug: Dietary therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary therapy received by diagnosed dietary therapy candidates according to NCEP II guidelines
Trial: 11184063
Drug: Dietary therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary therapy received by diagnosed dietary therapy candidates according to European guidelines
Trial: 11184063
Drug: Antilipemic drug
RxNorm normalized name: ANTILIPEMIC AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antilipemic drug therapy received by diagnosed drug therapy candidates according to NCEP II guidelines
Trial: 11184063
Drug: Antilipemic drug
RxNorm normalized name: ANTILIPEMIC AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antilipemic drug therapy received by diagnosed drug therapy candidates according to European guidelines
Trial: 11184063
Drug: Diagnosis of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diagnosis of high blood cholesterol levels among NCEP II drug therapy candidates
Trial: 11184063
Drug: Diagnosis of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diagnosis of high blood cholesterol levels among European drug therapy candidates
Trial: 8270437
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy plus hyperthermia
Trial: 31586600
Drug: SB206 4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB206 4% twice daily
Trial: 31586600
Drug: SB206 8%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB206 8% twice daily
Trial: 31586600
Drug: SB206 12%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB206 12% twice daily
Trial: 31586600
Drug: SB206 12%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB206 12% once daily
Trial: 31586600
Drug: SB206 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB206 (all doses)
Trial: 31586600
Drug: SB206 4%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB206 4%, 8%, and 12% twice daily
Trial: 30630791
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (exposed to clopidogrel and aspirin)
Trial: 30630791
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not exposed to clopidogrel and aspirin)
Trial: 26073395
Drug: 0 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g/d EPA + DHA (placebo)
Trial: 26073395
Drug: 0.85 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.85 g/d EPA + DHA (low dose)
Trial: 26073395
Drug: 3.4 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.4 g/d EPA + DHA (high dose)
Trial: 23750465
Drug: High treatment
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High treatment dose (high attendance, exposure completion)
Trial: 23750465
Drug: Low treatment
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low treatment dose (low attendance, exposure completion)
Trial: 21445641
Drug: Intravenous selenite
RxNorm normalized name: selenite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous selenite as a bolus-loading dose of 2,000 μg Se followed by continuous infusion of 1,600 μg Se per day for 10 days
Trial: 21445641
Drug: Intravenous selenite
RxNorm normalized name: selenite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous selenite
Trial: 18279770
Drug: Irbesartan (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (not specified dosage or duration)
Trial: 14586350
Drug: Combination misoprostol-Foley
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination misoprostol-Foley catheter
Trial: 10722450
Drug: Intranasal zanamivir
RxNorm normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intranasal zanamivir
Trial: 11058672
Drug: Inhaled zanamivir
RxNorm normalized name: zanamivir Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled zanamivir
Trial: 10722450
Drug: Inhaled plus
RxNorm normalized name: Duramist Plus Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled plus intranasal zanamivir
Trial: 7788012
Drug: GHRH, Insulin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH, Insulin, Clonidine